Clinical Trials
23 trialsOptimum Induction Therapy of Low-risk APL
Peking University People's Hospital
National Acute Promyelocytic Leukemia (APL) Observational Study NAPOLEON-Registry of the German AML Intergroup
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
Effectiveness and Safety of Therapy Based on Attenuated ATO Plus Low-Dose ATRA in Patients With APL
Hospital Universitario Dr. Jose E. Gonzalez
Oral Arsenic Trioxide for Newly Diagnosed Acute Promyelocytic Leukaemia
The University of Hong Kong
The Acute Promyelocytic Leukaemia Asian Consortium (APL-AC) Project
The University of Hong Kong
APL0618
Gruppo Italiano Malattie EMatologiche dell'Adulto
APL16
First Affiliated Hospital Xi'an Jiaotong University
Long-term QoL in Acute Promyelocytic Leukemia Treated With ATO or Standard Chemotherapy
Gruppo Italiano Malattie EMatologiche dell'Adulto
"AIDA" Protocol (LAP 0493)
Gruppo Italiano Malattie EMatologiche dell'Adulto
AIDA 2000 Guidelines
Gruppo Italiano Malattie EMatologiche dell'Adulto
RIF
Peking University People's Hospital
Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Shanghai Jiao Tong University School of Medicine
Role of Microparticles in the Coagulopathy of Acute Promyelocytic Leukemia
First Affiliated Hospital of Harbin Medical University
Treatment Study for Children and Adolescents With Acute Promyelocitic Leukemia
Associazione Italiana Ematologia Oncologia Pediatrica
Acute Promyelocytic Leukemia 2006 (APL)
Assistance Publique - Hôpitaux de Paris
Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission
National Cancer Institute (NCI)
Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
PIAPL
Christian Medical College, Vellore, India
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
National Cancer Institute (NCI)
AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
Technische Universität Dresden
Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia
NuRx Pharmaceuticals, Inc.
Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic
German AML Cooperative Group
IAPLSG04
Christian Medical College, Vellore, India